[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-metastatic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,53,85,106,131,160,190,229,260,283,304,330],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":52},"100471453","phase-2-a-study-of-stereotactic-radiosurgery-srs-for-people-with-lung-cancer-that-has-spread-to-the-brain-100471453",false,"NCT05419076","A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain","A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Histologic diagnosis of small cell lung cancer\n* Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI\n* Age 18 and above\n* Performance status KPS 60-100\u002FECOG 0-2\n* Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment\n* The patient or legally authorized representative is able to provide informed consent\n\nExclusion Criteria:\n\n* Unable to undergo contrast-enhanced MRI brain\n* Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine\n* Pregnant or lactating women\n* Prior brain-directed radiotherapy\n* Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET\u002FCT imaging, no more than 3 months before study enrollment","ALL","18 Years",{"count":19,"type":20},62,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of the study is to see if stereotactic radiosurgery\u002FSRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer\u002FSCLC.",[26,27,28,29,30,31],"Lung Cancer","Lung Cancer Metastatic","Brain Metastases","Brain Metastases, Adult","Small-cell Lung Cancer","Small Cell Lung Carcinoma",[33,34,35,36,37,38,39,40],"Stereotactic Radiosurgery","small cell lung cancer","small cell lung carcinoma","lung cancer","lung cancer metastatic","brain metastases","22-133","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-06-09",{"date":44,"type":45},"2026-06-10","ACTUAL",{"date":47,"type":45},"2022-06-10",{"date":49,"type":20},"2027-06-10",{"name":40,"class":51},"OTHER",7,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":71,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100638863","phase-3-evaluate-bl-m14d1-plus-atezolizumab-vs-standard-of-care-in-first-line-extensive-stage-small-cell-lung-cancer-100638863","NCT07625644","Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer","A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)\n* Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.\n* At least one measurable lesion based on RECIST v1.1 per investigator assessment.\n* An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.\n* Participants who have received prior topoisomerase inhibitor-based ADC therapy.\n* Participants with history of severe heart disease\n* Participants with active autoimmune diseases and inflammatory diseases,\n* Participants with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and\u002For carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",{"count":61,"type":20},550,[63],"PHASE3","The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).",[66,30,67,68,69,26,27,70],"Small Cell Lung Cancer Extensive Stage","Small Cell Carcinoma","Sclc","SCLC,Extensive Stage","Lung Cancer Stage IV",[72,73],"DLL3","First Line","NOT_YET_RECRUITING","2026-05-28",{"date":77,"type":45},"2026-06-04",{"date":79,"type":20},"2026-06",{"date":81,"type":20},"2031-06",{"name":83,"class":84},"SystImmune Inc.","INDUSTRY",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100631009","phase-1-phase-1b-trial-of-intratumoral-cisplatin-for-stage-iv-lung-cancer-100631009","NCT07495098","Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer","2.5.1 Inclusion criteria\n\n* Age 18 years or above\n* Eastern Cooperative Oncology Group (ECOG) performance score 0-2\n* Have known or suspected metastatic NSCLC at time of enrollment (including patients who progress on initial therapy or are found to have metastatic disease during therapy and are not excluded\n* Patient is able and willing to provide informed consent.\n* Rapid on-site cytopathologic examination (ROSE) performed during the procedure (if not previously diagnosed) and returns likely NSCLC. No injection will be performed if ROSE is non-diagnostic.\n* A CT scan of the chest (with or without contrast) within the prior 3 months.\n* The presence of an EBUS accessible target site determined by a treating investigator. These may be primary lung cancers or metastatic sites (including when a lymph node station has been replaced by metastatic tumor), that are accessible by EBUS.\n* MDC agreement of likely Stage IV NSCLC (confirmation from at minimum a Medical Oncologist and Radiation Oncologist on clinical stage).\n* Patients must have adequate organ and marrow function as defined below:\n\n  * Leukocytes ≥3,000\u002FmcL\n  * Platelets ≥100,000\u002FmcL\n  * Total bilirubin ≤ institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤ institutional ULN\n  * Creatinine ≤ institutional ULN\n\n2.5.2 Exclusion criteria\n\n* Use of an investigational agent in prior 30 days\n* Pregnancy\u002Flactation (pregnancy test to be performed by pre-op as part of standard of care for women of child-bearing age as defined by UVMMC Policy NPREP16)\n* Treatment with intravenous cytotoxic chemotherapy within the past 14 days\n* Allergy to cisplatin or its derivatives\n* Allergy to iodinated contrast\n* Patient not appropriate for the research study based on physician discretion",{"count":5,"type":20},[93],"PHASE1","The addition of intravenous (given through a vein) cisplatin to immunotherapy improves treatment outcomes for lung cancer, but unfortunately results in significantly more side effects since the rest of the body is exposed to significant amounts of the drug. Our clinical trial data indicate that injecting cisplatin directly into the tumor using a bronchoscope (a small flexible tube with a camera in it) has very few side effects, and results in significant cell death and potentially improvement in the immune response. The goal of this proposal is to evaluate a computational approach, that incorporates data from a CT scan, to determine the optimal dose and delivery location within a tumor to maximize tumor cell killing and the immune response.",[27,96],"Lung Cancer (NSCLC)","2026-03-20",{"date":99,"type":45},"2026-03-27",{"date":101,"type":20},"2026-07-01",{"date":103,"type":20},"2031-06-30",{"name":105,"class":51},"University of Vermont",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100473985","phase-1-fluorine-18-alphavbeta6-binding-peptide-positron-emission-tomography-in-metastatic-non-small-cell-lung-cancer-100473985","NCT05452005","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Men and women age \\>18 yrs\n2. Biopsy proven NSCLC with brain metastases (treated or untreated)\n3. Life-expectancy of ≥3 months in the opinion of the treating physician\n4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.\n5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan\n6. Ability to understand and willingness to sign a written informed consent document.\n7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging\n8. \\[18F\\]-FDG PET\u002FCT within 21 days of enrollment\n9. MRI brain within 21 days of enrollment\n10. Eastern Cooperative Oncology Group Performance Status ≤ 2\n11. Glomerular filtration rate (GFR) ≥ 60\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Prisoners\n3. Concurrent malignancy of a different histology that could confound imaging interpretation\n4. Patients who cannot undergo PET\u002FCT scanning because of weight limits(\\>350lbs)",{"count":114,"type":20},20,[93],"This study investigates fluorine-18-AlphaVBeta6-BP (\\[18F\\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \\[18F\\]-αvβ6-BP PET\u002FComputed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.",[26,27,28,118],"Non Small Cell Lung Cancer",[120],"Positron Emission Tomography","2026-02-23",{"date":123,"type":45},"2026-02-27",{"date":125,"type":45},"2022-09-13",{"date":127,"type":20},"2026-12-31",{"name":129,"class":51},"University of California, Davis",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100533631","phase-1-a-study-assessing-kb707-for-the-treatment-of-advanced-solid-tumor-malignancies-affecting-the-lungs-100533631","NCT06228326","A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","KB707-02: A Phase 1\u002F2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs","KYANITE-1","Key Inclusion Criteria:\n\n* Age 18 years or older at the time of informed consent\n* Life expectancy \\>12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have at least one measurable lung lesion per RECIST v1.1 at Screening\n* Cohorts 1 through 4 only: Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or has no standard of care therapy.\n* Cohorts 5, 6, and 7 only: (1) Histologically or cytologically confirmed diagnosis of stage 3 or 4 NSCLC, as per American Joint Committee on Cancer (AJCC) staging system (8th edition) and (2) Subject must meet the following criteria of prior lines of therapy:\n\n  1. Subject has previously received no more than one line of prior immune checkpoint inhibitor (ICI) with or without platinum-based chemotherapy, or no more than two prior lines of therapy when given the ICI and platinum-based chemotherapy sequentially as two separate lines.\n  2. Subjects with an actionable mutation (e.g., EGFR, KRAS, ALK, or ROS1 genomic alteration), are permitted to have received one additional line of approved targeted therapy.\n\nKey Exclusion Criteria:\n\n* Not fully recovered from prior surgery or radiotherapy, including all radiation-related toxicities\n* The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707\n* Have known history of positive human immunodeficiency virus (HIV 1\u002F2)\n* Cohorts 5, 6, and 7 only:\n\n  1. Subject has a known additional malignancy that is progressing or requires active treatment\n  2. Subject has active brain metastases or leptomeningeal metastases\n  3. Prior anti-PD-1\u002FPD-L1 therapy was intolerable and required discontinuation of treatment\n  4. Subject has active, known, or suspected autoimmune disease requiring systemic treatment\n  5. Subject has known acute or chronic hepatitis\n  6. Subject has active pneumonitis or history of ICI-induced pneumonitis that required steroids",{"count":140,"type":20},250,[93,23],"The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies.\n\nThis is a Phase 1\u002F2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707.\n\nMonotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase.\n\nCombination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks.\n\nAll subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.",[144,27,145,146,96],"Lung Cancer, Non-small Cell","Solid Tumor, Adult","Advanced Cancer",[148,149,36],"cancer","Krystal Biotech","2025-10-22",{"date":152,"type":45},"2025-10-24",{"date":154,"type":45},"2024-04-17",{"date":156,"type":20},"2028-07",{"name":158,"class":84},"Krystal Biotech, Inc.",14,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":171,"conditions":172,"keywords":176,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":130},"100594950","clinical-application-study-of-petct-for-differential-diagnosis-of-non-small-cell-lung-cancer-100594950","NCT07026110","Clinical Application Study of PET\u002FCT for Differential Diagnosis of Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Imaging studies suspecting non-small cell lung cancer;\n3. Solid lung nodules (≥8 mm in diameter) diagnosed by chest ct, which are subject to 18F-FDG PET\u002FCT and surgical resection\u002Fbiopsy of lung nodules according to the NCCN guideline specifications for NSCLC in the 2024 edition;\n4. Patients or family members agreed to participate in this clinical study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Women during pregnancy and lactation;\n2. Persons with a history of surgery and trauma that significantly affects metabolic distribution and anatomical structure;\n3. Persons with severe other systemic diseases or known hypersensitivity to humanized monoclonal antibody products;\n4. Patient is unable to cooperate in completing the PET\u002FCT examination;\n5. Patient has participated in other clinical studies within the past year that have resulted in radiation exposures in excess of an effective dose of 50 mSv, in addition to the radiation exposures anticipated from participation in this clinical study;\n6. Patient should not participate in this clinical trial in the opinion of the investigator.","80 Years",{"count":168,"type":20},100,[170],"NA","This study aims to explore the efficacy of Trop2, EpCAM-specific PET\u002FCT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET\u002FCT examinations and conventional 18F-FDG PET\u002FCT in the diagnosis and differential diagnosis of solid lung nodules.",[26,173,174,27,175],"Lung Diseases","Lung Neoplasms","Lung Inflammation",[177,178,179,180],"Trophoblast cell surface antigen 2 (Trop2)","Epithelial cell adhesion molecule(EpCAM)","ImmunoPET","Lung tumor","2025-06-10",{"date":183,"type":45},"2025-06-18",{"date":185,"type":45},"2024-12-23",{"date":187,"type":20},"2026-10-31",{"name":189,"class":51},"RenJi Hospital",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":217,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100445254","phase-3-study-comparing-the-standard-administration-of-io-versus-the-same-io-administered-each-3-months-in-patients-in-response-after-6-months-of-standard-io-100445254","NCT05078047","Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO","MOIO","Inclusion Criteria:\n\n1. Patients must have signed a written informed consent form prior to any trial specific procedures.\n2. Patient aged ≥18 years old.\n3. Metastatic disease (or locally advanced disease not suitable for local treatment) of initial tumor histologically confirmed including: lung cancer, renal cell cancer, head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, hepatocellular carcinoma, melanoma, colorectal carcinoma with microsatellite instability \\[MSI\\], esophageal squamous cell carcinoma, endometrial carcinoma,cervical cancer, gastric\u002Fgastro-oesophageal junction adenocarcinoma, basal cell carcinoma or squamous skin carcinoma.\n4. Patients in partial or complete response after 6 months of standard immunotherapy (whatever the line of therapy) according to the RECIST or PERCIST v1.0 criteria (confirmed by local radiological assessment).\n\n   For metastatic melanoma only patients in partial response. Patients with metastatic or advanced cancer treated by immunotherapy as maintenance therapy can be included without any lesion at IO initiation. In this case, response after 6 months of standard immunotherapy will be evaluated by the non-appearance of a new lesion.\n5. Eligible to maintain the same standard IO treatment.\n6. Patient with Eastern cooperative oncology group (ECOG) performance status ≤1.\n7. Patients with brain metastases are allowed, provided they are stable according to the following definitions: treated with surgery or stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.\n8. Patients treated by IO previously combined with chemotherapy are allowed.\n9. Patients with Tyrosine Kinase Inhibitor (TKI)-IO or pemetrexed-IO or bevacizumab-IO are allowed.\n10. Evidence of post-menopausal status, or negative urinary or serum pregnancy test for pre-menopausal patients.\n11. Both sexually active women of childbearing potential and males (and their female partners) patients must agree to use adequate contraception method for the duration of the study treatment and after completing treatment according to the most recent version of the IO Summary of product characteristics (SmPC).\n12. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.\n13. Patient must be affiliated to a Social Security System.\n\nExclusion Criteria:\n\n1. Metastatic melanoma in complete response.\n2. Metastatic renal cell carcinoma with International Metastatic Renal Cell Carcinoma Database (IMDC) favourable-risk treated TKI\u002FIO combination.\n3. Hematologic malignancies (leukaemia, myeloma, lymphoma…)\n4. Active infection requiring systemic therapy.\n5. Patients enrolled in another therapeutic study within 30 days before the inclusion in and during MOIO study.\n6. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study.\n7. Person deprived of their liberty or under protective custody or guardianship.",{"count":199,"type":20},646,[63],"Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as the current standard treatment in term of prevention of the disease progression. If proved right, this study will have a positive medico-economic impact by reduction of the costs associated with the treatment and the toxicity, and an increase of the patients' quality of life.",[27,203,204,205,206,207,208,209,210,211,212,213,214,215,216],"Renal Cell Carcinoma","Head and Neck Cancer","Triple Negative Breast Cancer","Merkel Cell Carcinoma","Hepatocellular Carcinoma","Melanoma","Urothelial Carcinoma","Colorectal Carcinoma With Microsatellite Instability","Esophageal Squamous Cell Carcinoma","Endometrial Carcinoma","Cervical Cancer","Gastric\u002FGastro-esophageal Junction\u002FEsophageal Adenocarcinoma","Basal Cell Carcinoma","Squamous Skin Carcinoma",[218],"Immunotherapy","2025-06-04",{"date":221,"type":45},"2025-06-05",{"date":223,"type":45},"2022-03-08",{"date":225,"type":20},"2027-03-07",{"name":227,"class":51},"UNICANCER",40,{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":237,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":130},"100557430","phase-1-til-therapy-combined-with-pembrolizumab-for-advanced-or-metastatic-refractory-lung-cancer-100557430","NCT06538012","TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer","Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab Immunotherapy in Patients With Advanced or Metastatic Refractory Lung Cancer","BAH2472","Inclusion Criteria:\n\n* Age: 16 years to 90 years\n* Histologically diagnosed as primary\u002Frelapsed\u002Fmetastasized Lung cancer\n* Expected life span more than 3 months\n* Karnofsky≥60% or ECOG score 0-2\n* Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.\n* Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated\n* At least 1 evaluable tumor lesion\n* Hematology and Chemistry（within 7 days prior to enrollment）:\n* Absolute count of white blood cells≥2.5×10\\^9\u002FL\n* Absolute count of neutropils≥1.5×10\\^9\u002FL\n* Absolute count of lymphocytes ≥0.7×109\u002FL\n* Platelet count≥100×10\\^9\n* hemoglobin≥90 g\u002FL\n* Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* Serum creatinine ≤1.5mg\u002FdL(or ≤132.6μmol\u002FL), or clearance rate≥50mL\u002Fmin\n* Serum ALT\u002FAST ≤3×ULN(subjects with liver metastasis ≤3×ULN)\n* Totol bilirubin≤1.5×ULN\n* No absolute or relative contraindications to operation or biopsy\n* Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent and continue within 1 year after the completion of lymphodepletion\n* Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs\n* Be able to understand and sign the informed consent document;\n* Be able to stick to follow-up visit plan and other requirements in the agreement.\n\nExclusion Criteria:\n\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment\n* Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%\n* Significant cardiovascular anomalies according to any of the following definitions:\n* New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant\n* Low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular conductive block, etc.\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive.\n* Severe physical or mental diseases;\n* Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection).\n* Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy.\n* History of allergy to chemical compounds consisting of chemical and biological substances resembling cell therapy.\n* Having received immunotherapy and developed an irAE level greater than Level 3.\n* Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded).\n* Females in pregnancy or lactation. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy.\n* Researchers consider the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.","16 Years","90 Years",{"count":240,"type":20},85,[93,23],"This Phase I\u002FII study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory lung cancer. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has demonstrated significant success in treating unresectable or metastatic melanoma by utilizing the patient's own immune cells to combat cancer. This study aims to apply a similar approach to lung cancer. TILs will be harvested from patients' tumors, expanded in vitro, and infused back into the patients following a non-myeloablative lymphodepletion regimen. Pembrolizumab, a monoclonal antibody targeting the PD-1 receptor on T cells, will be administered to enhance the immune response. The primary endpoint is to determine the objective response rate (ORR) of this combined therapy. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This trial aims to offer a novel, personalized treatment option for patients with limited therapeutic alternatives.",[26,27,144,244],"Lung Cancer Recurrent",[246,247,248,249,218,250],"Tumor Infiltrating Lymphocytes","CAR-T CELL","Biological Therapy","Advanced or Metastatic Refractory","TIL","2024-10-11",{"date":253,"type":45},"2024-10-15",{"date":255,"type":45},"2024-08-20",{"date":257,"type":20},"2026-12-28",{"name":259,"class":51},"Essen Biotech",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":130},"100558176","primary-tumor-resection-for-m1a-stage-lung-cancer-100558176","NCT06547710","Primary Tumor Resection for M1a Stage Lung Cancer","Primary Tumor Resection for M1a Stage Lung Cancer With Occult Pleural Dissemination Discovered During Surgery: a Prospective, Single-arm, Multi-center, Phase Ⅱ Trial","ECTOP-1023","Inclusion Criteria:\n\n1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;\n2. Aged 18-80 years (including critical values) when signing the informed consent form;\n3. ECOG score 0 or 1;\n4. No previous lung cancer surgery;\n5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;\n6. Occult pleural metastasis found during surgery;\n7. Preoperative lymph node staging is cN0;\n8. First-time treatment and no radiotherapy or chemotherapy.\n\nExclusion Criteria:\n\n1. The lesion cannot be completely removed surgically;\n2. Cytological or histological pathology confirms other lung malignancies other than lung cancer;\n3. Patients who have undergone lung cancer surgery before;\n4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.","75 Years",{"count":270,"type":20},66,"OBSERVATIONAL","This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.",[27,274],"Surgical Resection","2024-08-07",{"date":277,"type":45},"2024-08-09",{"date":279,"type":45},"2024-04-01",{"date":79,"type":20},{"name":282,"class":51},"Fudan University",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":130},"100369053","phase-1-alisertib-in-combination-with-osimertinib-in-metastatic-egfr-mutant-lung-cancer-100369053","NCT04085315","Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","A Phase I\u002FIb Study of Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","Inclusion Criteria:\n\n1. Patients must have histologically confirmed stage IV non-small cell lung cancer.\n2. Male or female patients \\>=18 years of age\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Documented activating EGFR mutation (Exon 19 deletion, Exon 19 insertion, E709K, G719X, S768I, V769L, T790M, L833F, L833V, V834L, H835L, L858R, A859S, K860I, L861Q, A871E, V843I, or H870R) on tumor sample or cell-free DNA sample performed in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.\n5. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.\n6. Clinical laboratory values as specified below within 7 days before the first dose of study drug (if applicable):\n\n   1. Absolute neutrophil count (ANC) \\> 1500\u002Fmm\\^3\n   2. Absolute lymphocyte count \\> 500 mm\\^3\n   3. Platelets \\> 100,000\u002Fmm\\^3\n   4. Hemoglobin (Hgb) \\> 9 g\u002FdL. Values must be obtained without need for red blood cell transfusion support within 14 days. However, erythrocyte growth factor is allowed as per published American Society of Clinical Oncology (ASCO) guidelines.\n   5. Total bilirubin ≤ 1.5 x upper limit of normal (ULN). Patients with Gilbert's syndrome may be allowed on study if total bilirubin is \\\u003C= 3 x upper limit of normal (ULN) if direct bilirubin is \\\u003C= 1.5 x upper limit of normal (ULN).\n   6. Serum glutamic-oxaloacetic transaminase (SGOT) \u002F aspartate aminotransferase (AST) and serum glutamic-pyruvic transaminase (SGPT) \u002F alanine aminotransferase (ALT) \\\u003C 2.5 x ULN. AST and\u002For ALT may be up to 5 x ULN if with known liver metastases.\n   7. Renal function as defined by calculated creatinine clearance \\>=30 ml\u002Fmin (Cockcroft-Gault Formula).\n7. Willing to provide blood and tissue for correlative research purposes.\n8. Willing to undergo pre-treatment research biopsy, OR donate archived tissue from a biopsy performed within 60 days of the first dose of study drug is available.\n9. Female patients who:\n\n   1. Are postmenopausal (see Appendix 6) for at least 1 year before the screening visit, OR\n   2. Are surgically sterile, OR\n   3. If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time (see Appendix 6), from the time of signing the informed consent through 180 days after the last dose of study drug, OR\n   4. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)\n10. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:\n\n    1. Agree to practice effective barrier contraception during the entire study treatment period and through 120 after the last dose of study drug, OR\n    2. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)\n11. Voluntary written consent must be given before performance of any study-related procedure not part of standard of care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.\n12. Currently receiving and tolerating osimertinib 80 mg PO daily with no current grade 2 or greater AE attributable to osimertinib.\n13. Evidence of disease progression on imaging (computerized tomography (CT) scan, magnetic resonance imaging (MRI), or Positron Emission Tomography (PET) CT within the last 30 days.\n14. Resolution of all acute toxic effects of prior chemotherapy, immunotherapy, radiotherapy or surgical procedures to less than or equal to grade 2 per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.\n\n    Inclusion Criteria (Cohort A): Must meet inclusion criteria below in addition to 1-14 above:\n15. Patients must have received no more than one additional line of systemic therapy to treat lung cancer other than osimertinib (re-treatment with osimertinib after other systemic lung cancer therapy will not count as a line of therapy). A line of therapy equals at least one month of treatment with discontinuation of therapy due to disease progression or intolerability. Patients who have received adjuvant or neoadjuvant osimertinib, chemotherapy, or immunotherapy for surgically resectable NSCLC, or chemotherapy + radiation +\u002F- immunotherapy for locally advanced NSCLC, will not be considered a line of therapy if it is equal to or greater than 12 months since completing their treatment.\n16. Patients must be currently receiving osimertinib 80 mg for the treatment of metastatic disease or have evidence of metastatic disease recurrence while receiving adjuvant osimertinib therapy.\n\n    Inclusion Criteria (Cohort B): Must meet inclusion criteria below in addition to 1-7, 9-12, and 14. Inclusion criteria 8 and 13 are not required. The following inclusion criteria must also be met:\n17. Currently receiving osimertinib 80 mg as 1st line therapy for metastatic NSCLC. Patients who have received adjuvant or neoadjuvant, chemotherapy, or immunotherapy for surgically resectable NSCLC, or chemotherapy + radiation +\u002F- immunotherapy for locally advanced NSCLC, will be allowed if it is equal to or greater than 12 months since completing their treatment.\n18. Meet RECIST 1.1 criteria for PR or SD to osimertinib, including a confirmation scan.\n19. Have received osimertinib 80 mg for a minimum of 90 days, but no more than 180 days.\n\n    Inclusion Criteria (Cohort C): Must meet inclusion criteria 1-7 and 9-16 above. The following inclusion criterion must also be met:\n20. Willing to undergo pre-treatment research biopsy, if deemed safe by the investigator, or willing to donate archived tissue from a biopsy performed within 60 days prior to the first dose of study drug. Note: Pre-treatment tissue is mandatory for Cohort C and will be used for a CLIA-approved TP53 mutation test during screening. To be eligible for Cohort C, patients must not have a known TP53 missense mutation, nonsense mutation, frameshift mutation, in frame deletion, or whole gene deletion (see also exclusion criterion #22).\n\nExclusion Criteria\n\n1. Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is considered to be over 25%.\n2. Prior allogeneic bone marrow or organ transplantation\n3. Known Gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib. Examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease\n4. Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib.\n5. Known history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen.\n6. Requirement for constant administration of proton pump inhibitor, Histamine 2 (H2) antagonist, or pancreatic enzymes throughout the study. The intermittent use of H2-antagonists and antacids (including carafate) is only allowed within these guidelines:\n\n   1. H2 antagonists until Day -1 and after the dosing of alisertib is done\n   2. Antacid formulations until 2 hours before dosing and after 2 hours following dosing.\n   3. Proton Pump Inhibitor (PPI) is allowed until Day -5 of first alisertib dose. PPIs are prohibited throughout the study.\n7. Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any electrocardiogram (ECG) abnormality at Screening has to be documented by the investigator as not medically relevant.\n8. QT interval corrected (QTc) using Fridericia's method (QTCF) \\> 470 milliseconds (msec). The following formula can be used to calculate QTcF for subjects with a wide QRS complex caused by the bundle branch block, QTcF = measured QTcF - (QRS - 100msec).\n9. Female subject who is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (Beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.\n10. Female patient who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).\n11. Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).\n12. Other severe acute or chronic medical or psychiatric condition, including uncontrolled diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement for pancreatic enzymes, any condition that would modify small bowel absorption of oral medications, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study.\n13. Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer or breast cancer, or thyroid cancer after curative therapy\n14. Patients who are currently receiving treatment with contraindicated QTcF prolonging medications or potent CYP3A4 inducers\u002Finhibitors if that treatment cannot be either discontinued or switched to a different medication prior to first day of study treatment.\n15. Patients with central nervous system (CNS) metastases who are neurologically unstable (as defined by need for steroids in last 14 days).\n16. Known leptomeningeal carcinomatosis.\n\n    Exclusion Criteria (Cohort A): Must meet exclusion criteria 1-16 above. The following exclusion criteria must also be met:\n17. Known small cell lung cancer transformation on osimertinib resistance biopsy.\n18. Known EGFR C797S osimertinib resistance mutation, hepatocyte growth factor receptor (MET) amplification, oncogenic fusion involving neurotrophic tyrosine receptor kinase (NTRK), RET, ALK, ROS-1, or BRAF, BRAF V600E, or oncogenic KRAS mutation determined by Clinical Laboratory Improvement Amendments (CLIA)-approved test on osimertinib resistance biopsy or cell-free deoxyribonucleic acid (DNA) test performed at osimertinib resistance.\n\n    Exclusion Criteria (Cohort B): Must meet exclusion criteria 1-16 above. The following exclusion criteria must also be met:\n19. Evidence of complete response (CR) or progressive disease (PD) to osimertinib by RECIST 1.1 criteria on imaging within 30 days prior to starting alisertib.\n20. Prior treatment with adjuvant osimertinib.\n21. Prior treatment with an EGFR TKI other than osimertinib.\n\n    Exclusion Criteria (Cohort C): Must not meet exclusion criteria 1-18 above. The following exclusion criterion must also not be met:\n22. Known TP53 missense mutation, nonsense mutation, frameshift mutation, in frame deletion, or whole gene deletion determined by CLIA-approved test on any prior patient lung cancer biopsy.",{"count":291,"type":20},38,[93],"This phase I\u002FIb trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for the growth of lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and\u002For bad, it has on EGFR-mutated lung cancer.",[27,295],"EGFR Gene Mutation","2024-06-06",{"date":298,"type":45},"2024-06-10",{"date":300,"type":45},"2019-11-12",{"date":127,"type":20},{"name":303,"class":51},"Collin Blakely",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":21,"phases":314,"briefSummary":315,"conditions":316,"keywords":317,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":130},"100393619","phase-2-stereotactic-ablative-radiotherapy-for-oligo-progressive-non-small-cell-lung-cancer-100393619","NCT04405401","Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer","Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial","SUPPRESS-NSCLC","Inclusion Criteria:\n\n* Age ≥18 years\n* Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n* Oligoprogression to 1-5 extracranial lesions ≤ 5cm and involving ≤ 3 organs. Progression at the primary tumor site should be counted within the total of 5 lesions. For patients with lymph node metastases, each node is counted as one site of metastasis.\n* Oligoprogression while on ICI or TKI (any line)\n* Patients with brain metastasis are allowed; brain metastasis are not counted in the maximum number of lesions and should be treated as per standard of care\n* All sites of disease can, in the opinion of the investigator, be safely treated and targetable with SABR (taking into account prior local therapy, organ function and underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis, etc.)\n* Patients with prior metastases that have been treated with ablative therapies (e.g. radiotherapy, surgery or radiofrequency ablation) before their current line of systemic therapy, are eligible.\n\nExclusion Criteria:\n\n* Any lesion beyond 5 cm\n* Pregnancy or breastfeeding\n* Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy.\n* Presence of spinal cord compression Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel)",{"count":313,"type":20},68,[23],"A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.",[27],[318,319,320],"non small cell lung cancer","oligoprogression","steretactic body radiotherapy","2023-12-11",{"date":323,"type":45},"2023-12-12",{"date":325,"type":45},"2021-01-05",{"date":327,"type":20},"2027-07-01",{"name":329,"class":51},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":354},"100480587","i3lung-integrative-science-intelligent-data-platform-for-individualized-lung-cancer-care-with-immunotherapy-100480587","NCT05537922","I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C\u002F= 2.\n* Histologically confirmed diagnosis of stage IIIB\u002FC-IV Non-Small-Cell Lung Cancer\n* Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective cohort; clinical indication for frontline treatment with immunotherapy as first line treatment for prospective cohort.\n* Patients with CNS metastasis are allowed\n* Patients with driver genomic alterations are allowed (only for retrospective cohort)\n* Evidence of a personally signed and dated ICF indicating that the patient has been informed of and understands all pertinent aspects of the study before enrolment (only for prospective cohort)\n* Availability of at least one FFPE block for -omics data generation (only for prospective cohort)\n\nExclusion Criteria:\n\n* Patients without minimal treatment information data to be included in the retrospective cohort\n* Prior treatment for advanced disease (only for prospective cohort)\n* Unavailability or inability to comply with the requested study procedures, including compilation of QoL questionnaires",{"count":337,"type":20},2200,"I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase.\n\nThe retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs.\n\nThe prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients. This cohort will be used to validate the results obtained from the retrospective model through the creation of a new model (P-Model), which will be used to create the final PDSS tool.",[118,27,340,341],"Lung Cancer, Nonsmall Cell","Lung Adenocarcinoma",[343,344,218],"NSCLC","Artificial Intelligence","2023-01-05",{"date":347,"type":45},"2023-01-06",{"date":349,"type":45},"2022-10-01",{"date":351,"type":20},"2027-10-01",{"name":353,"class":51},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",4]